<DOC>
	<DOCNO>NCT00677638</DOCNO>
	<brief_summary>A prospective single arm study evaluate feasibility safety catheter-based transapical implantation Ventor Embracer™ aortic valve bioprosthesis patient severe aortic valve disease , specifically aortic stenosis , elevate risk standard surgical valve replacement .</brief_summary>
	<brief_title>Transapical Implantation Ventor Embracer™ Valve Patients With Severe Aortic Valve Disease</brief_title>
	<detailed_description />
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<criteria>1 . Patient understands implication participate study provide informed consent 2 . Patient willing comply specify followup evaluation contact telephone 3 . Age &gt; 75 year 4 . Severe , aortic stenosis ( echocardiographically derive mean gradient &gt; 40 mm Hg , and/or jet velocity &gt; 4m/s , initial aortic valve area &lt; 0.8 cm2 ) 5 . Symptoms related aortic valve disease , demonstrate NYHA Functional Class II great 6 . EuroSCORE scale &gt; 9 point indicate predict risk mortality &gt; 11 % accord logistic EuroSCORE 7 . Echocardiographically determine anteroposterior aortic annulus diameter &gt; 19 &lt; 23 mm 8 . Echocardiographically determine sinotubular junction diameter ≥23 mm 1 . Congenital unicuspid bicuspid aortic valve 2 . Fused commissures 3 . Severe eccentricity calcification 4 . Echocardiographic evidence intracardiac mass , thrombus , vegetation . 5 . Severe leave ventricular dysfunction ( LVEF &lt; 25 % ) 6 . More mild right ventricular dysfunction 7 . Hypertrophic obstructive cardiomyopathy 8 . Moribund patient , patient noncardiac disease limit life expectancy le 12 month 9 . Known hypersensitivity contraindication study medication 10 . Known sensitivity contrast medium adequately control premedication 11 . Known allergy sensitivity Nitinol 12 . Sepsis , acute endocarditis 13 . Blood dyscrasia acute anemia , leucopenia , thrombocytopenia ; bleed diathesis , coagulopathy . 14 . Renal insufficiency and/or end stage renal disease require chronic dialysis 15 . Liver disease indicate jaundice , ascites , ALT/AST &gt; 3 x ULN , elevation total bilirubin &gt; 1.5 mg/dl , albumin &lt; 3.0 g/l , INR &gt; 1.5 ( anticoagulation ) . 16 . Significant lung disease ( e.g . FEV1 &lt; 1.2L FEV1 &lt; 50 % ) . 17 . Active peptic ulcer GI bleeding within 3 month plan index procedure 18 . Untreated clinically significant coronary artery disease require revascularisation 19 . Cardiogenic shock , suspect cardiogenic shock , hemodynamic instability require inotropic support mechanical heart assistance 20 . Peripheral vascular disease , include abdominal thoracic aortic disease , could pose problem eventual transarterial mechanical support ( e.g . Intraaortic Balloon Pump ) 21 . Need emergency surgery , cardiac noncardiac 22 . History myocardial infarction last 6 week . 23 . History TIA stroke last 6 month . 24 . Any therapeutic invasive cardiac procedure , except aortic balloon valvuloplasty , perform within 30 day plan index procedure , 6 month , case implantation drugeluting stent . 25 . Uncontrolled atrial fibrillation 26 . Preexisting aortic valve replacement 27 . Severe ( great 3+ ) mitral regurgitation 28 . Severe ( great 3+ ) aortic regurgitation 29 . Patient currently enrol another investigational device drug trial</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>